Calendar

Oct
7
Sun
Summit Meeting – San Diego, CA @ Marriott Marquis San Diego Marina
Oct 7 @ 6:00 pm – 7:45 pm

A 3D View: Improving Acute Preventive Treatment of Migraine in Primary Care Setting Using Novel Agents

Sunday, October 07, 2018

6:00 PM – 6:30 PM Registration/Dinner
6:30 PM – 7:45 PM Meeting

VENUE

Marriott Marquis San Diego Marina
333 West Harbor Drive
San Diego, CA 92101
Meeting Room: Ballroom 5-9

PROGRAM FEATURES

  • 1.15 CME Credits: A 3D View!
  • 3D Glasses Provided to all attendees
  • Interactive, case-based learning environment
  • Create your own Personalized Poster

REGISTRATION INFORMATION

To register for the live event meeting or simulcast, please visit www.MLG-Migraine.com or call 2017-406-4248.

FACULTY

Anne H. Calhoun, MD, FAHS
Partner/Co-Founder, Carolina Headache Institute
Professor, Department of Anesthesiology
Professor, Department of Psychiatry
University of North Carolina
Chapel Hill, NC

Andrew Charles, MD
Professor of Neurology
Director, UCLA Goldberg Migraine Program
Meyer and Renee Luskin Chair in Migraine and Headache Studies
David Geffen School of Medicine at
University of California,
Los Angeles, LA

AGENDA

I. Migraine: Overview

  • The burden of migraine: epidemiology, disability and quality of life, economic burden
  • Migraine pathophysiology
  • Migraine and other primary headaches: classification and diagnosis
  • Challenges of differential diagnosis

II. The Current Challenges and Needs in Migraine Management

  • Expanding role for primary care providers and doctors of osteopathy
  • Evidence-based approach to acute and preventive treatment of migraine
  • Abortive agents in development: lasmiditan, gepants, new delivery devices for existing agents
  • Migraine prevention: what are the current unmet needs?
  • Patient segmentation: identifying the patients with refractory chronic migraine

Patient video showing the process of differential diagnosis – leading in to treatment

III. Targeting CGRP or Its Receptor: A New Era in Targeting Migraine Underlying Pathology

  • Role of CGRP in the trigeminovascular system and in migraine
    • Mechanism of action of gepants and mAbs to CGRP or its receptor
  • Update of recently released data from clinical trials
  • Safety
  • Patient-reported outcomes
  • Adherence, persistence and cost-effectiveness, impact on access
  • Interactive case studies, including refractory chronic migraine cases

IV. Neuromodulation: A Brief Update

V. Clinician-patient Communication: Case-based Discussion

  • Improving patient/physician and physician/physician communication

VI. “Conclusions and Questions & Answers

EDUCATIONAL OBJECTIVES

  • Review best practices for diagnosing migraine headaches including the process of differential diagnosis
  • Assess efficacy and safety profiles of investigational agents for the acute treatment of migraine, as well as calcitonin-gene related peptide (CGRP)-targeting agents for the prevention of episodic and chronic migraine
  • Describe burdens associated with migraine headaches and the use of patient reported outcomes for measuring the impact of new and established migraine therapies
  • Discuss strategies for managing migraine that include the integration of novel treatment options and the application of methods for

TARGET AUDIENCE

This activity is intended for primary care providers and doctors of osteopathy working with patients with migraine headaches.

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.15 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in treating and managing patients with migraine. CNE Credits: 1.15 ANCC Contact Hours

CNE Accreditation Statement

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

ABIM MAINTENANCE OF CERTIFICATION

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.15 MOC in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

AOA CREDIT

Med Learning Group will apply to the American Osteopathic Association (AOA) Council on Continuing Medical Education to approve this symposium for AOA Category 2-A credits.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Med Learning Group prior to the live event at info@medlearninggroup.com

Nov
15
Thu
A 3D View: Improving Acute and Preventive Treatment of Migraine in the Primary Care Setting Using Novel Agents
Nov 15 2018 @ 12:00 am – Nov 15 2019 @ 12:00 am

A 3D View: Improving Acute Preventive Treatment of Migraine in Primary Care Setting Using Novel Agents

View Activity

FACULTY

Anne H. Calhoun, MD, FAHS
Partner/Co-Founder, Carolina Headache Institute
Professor, Department of Anesthesiology
Professor, Department of Psychiatry
University of North Carolina
Chapel Hill, NC

Andrew Charles, MD
Professor of Neurology
Director, UCLA Goldberg Migraine Program
Meyer and Renee Luskin Chair in Migraine and Headache Studies
David Geffen School of Medicine at
University of California
Los Angeles, CA

PROGRAM OVERVIEW

This case-based enduring activity will cover the treatment and management of patients with migraines.

TARGET AUDIENCE

This educational activity is intended for primary care providers and doctors of osteopathy working with patients with migraine headaches.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

  • Review best practices for diagnosing migraine headaches including the process of differential diagnosis
  • Assess efficacy and safety profiles of investigational agents for the acute treatment of migraine, as well as calcitonin-gene related peptide (CGRP)-targeting agents for the prevention of episodic and chronic migraine
  • Describe burdens associated with migraine headaches and the use of patient reported outcomes for measuring the impact of new and established migraine therapies
  • Discuss strategies for managing migraine that include the integration of novel treatment options and the application of methods for overcoming patient- and physician-dependent barriers in clinical practice

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.25 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in treating and managing patients with migraine. CNE Credits: 1.25 ANCC Contact Hours

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Anne Calhoun, MD, FAHS, is on the speakers’ bureau for Amgen, Avanir, Depomed, Eli Lilly, Merck, Pernix, and Teva. Dr. Calhoun is a consultant for Amgen, Depomed, Lilly, and Teva.

Andrew Charles, MD, is a consultant for Alder, Amgen, Biohaven, Eli Lilly, and eNeura.

CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:

Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group has nothing to disclose.
Ana Maria Albino, Program Manager of Med Learning Group has nothing to disclose.
Chris Drury, Scientific and Medical Services of Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at http://medlearninggroup.com/privacy‐policy/

RELEASE DATE: November 15, 2018

EXPIRATION DATE: November 15, 2019

View Activity

Copyright © 2018 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Dec
20
Thu
A 3D View: Improving Acute and Preventive Treatment of Migraine in the Primary Care Setting Using Novel Agents
Dec 20 2018 @ 12:00 am – Dec 17 2019 @ 12:00 am

A 3-D View: Improving Acute and Preventive Treatment of Migraine in the Primary Care Setting Using Novel Agents

View Activity

FACULTY

Andrew Charles, MD
Professor of Neurology
Director, UCLA Goldberg Migraine Program
Meyer and Renee Luskin Chair in Migraine and Headache Studies
David Geffen School of Medicine at
University of California
Los Angeles, CA

PROGRAM OVERVIEW

This case-based enduring activity will cover the treatment and management of patients with migraines.

TARGET AUDIENCE

This educational activity is intended for primary care providers and doctors of osteopathy working with patients with migraine headaches.

LEARNING OBJECTIVES

Upon completion of the CME activity, learners should be better able to:

  • Review best practices for diagnosing migraine headaches including the process of differential diagnosis
  • Assess efficacy and safety profiles of investigational agents for the acute treatment of migraine, as well as calcitonin-gene related peptide (CGRP)-targeting agents for the prevention of episodic and chronic migraine
  • Describe burdens associated with migraine headaches and the use of patient reported outcomes for measuring the impact of new and established migraine therapies
  • Discuss strategies for managing migraine that include the integration of novel treatment options and the application of methods for overcoming patient- and physician-dependent barriers in clinical practice

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.25 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in treating and managing patients with migraine. CNE Credits: 1.25 ANCC Contact Hours

CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

AOA Credit: The AOA Bureau of OMED is accredited by the American Osteopathic Association to provide osteopathic continuing medical education for physicians. The AOA Bureau of OMED, as a co-sponsor with Med Learning Group, designates this enduring program for a maximum of 1.25 AOA Category 2-A credits and will report CME and specialty credits commensurate with the extent of the physician’s participant in this online activity.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Andrew Charles, MD, is a consultant for Alder, Amgen, Biohaven, Eli Lilly, and eNeura.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:

Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group has nothing to disclose.
Ana Maria Albino, Program Manager of Med Learning Group has nothing to disclose.
Chris Drury, Scientific and Medical Services of Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at http://medlearninggroup.com/privacy‐policy/

RELEASE DATE: December 17, 2018

EXPIRATION DATE: December 17, 2019

View Activity

Copyright © 2018 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Jan
30
Wed
Summit Meeting – Miami, FL @ JW Marriott Marquis Miami
Jan 30 @ 5:30 pm – 7:30 pm

A 3D View: Improving Acute Preventive Treatment of Migraine in Primary Care Setting Using Novel Agents

WEDNESDAY, JANUARY 30, 2019

5:30 PM – 6:00 PM Registration / Dinner
6:00 PM – 7:30 PM Meeting

VENUE

JW Marriott Marquis Miami
255 Biscayne Blvd Way
Miami, FL 33131
Meeting Room: Plaza 4 & 5

1.5 CME/CNE Credits: A 3D View!

  • 3D GLASSES PROVIDED TO ALL ATTENDEES

Features:

  • Interactive, case-based learning environment
  • Create your own Personalized Poster
  • iPads provided to enhance learning experience and enable real-time Q&A

REGISTRATION INFORMATION

To register for the live event meeting or simulcast, please visit www.MLG-Migraine.com or call 207-406-4248.

FACULTY

Anne H. Calhoun, MD, FAHS
Partner/Co-Founder, Carolina Headache Institute
Professor, Department of Anesthesiology
Professor, Department of Psychiatry
University of North Carolina
Chapel Hill, NC 

Andrew Charles, MD
Professor of Neurology
Director, UCLA Goldberg Migraine Program
Meyer and Renee Luskin Chair in Migraine and Headache Studies
David Geffen School of Medicine at
University of California
Los Angeles, LA

AGENDA

I. Overview of headache disorders

  • The burden of migraine: epidemiology, disability and quality of life, economic burden
  • Migraine and other primary headaches: classification and diagnosis of primary headache disorders
  • Patient video showing the process of differential diagnosis – leading into treatment

II The current challenges and needs in migraine management

  • Expanding role for primary care providers and doctors of osteopathy
  • Evidence-based approach to acute and preventive treatment of migraine
  • Abortive agents in development: lasmiditan, gepants, new delivery devices for existing agents
  • Migraine prevention: what are the current unmet needs?
  • Improving patient/physician and physician/physician communication

III. Targeting CGRP or its receptor: a new era in targeting migraine underlying pathology

  • Role of CGRP in the trigeminovascular system and in migraine
    • Mechanism of action of gepants and mAbs to CGRP or its receptor
  • Update of recently released data from clinical trials
  • Safety
  • Patient-reported outcomes
  • Interactive case studies, including refractory chronic migraine cases
  • Improving patient/physician and physician/physician communication

IV. Neuromodulation: a brief update

V. Conclusions and Q&A

EDUCATIONAL OBJECTIVES

  • Review best practices for diagnosing migraine headaches including the process of differential diagnosis
  • Assess efficacy and safety profiles of investigational agents for the acute treatment of migraine, as well as calcitonin-gene related peptide (CGRP)-targeting agents for the prevention of episodic and chronic migraine
  • Describe burdens associated with migraine headaches and the use of patient-reported outcomes for measuring the impact of new and established migraine therapies
  • Discuss strategies for managing migraine that include the integration of novel treatment options and the application of methods for overcoming patient- and physician-dependent barriers in clinical practice

TARGET AUDIENCE
This activity is intended for primary care providers and doctors of osteopathy working with patients with migraine headaches.

ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.5 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in treating and managing patients with migraine. CNE Credits: 1.5 ANCC Contact Hours

CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

ABIM Maintenance of Certification:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 AOA Credit:
The AOA Bureau of OMED is accredited by the American Osteopathic Association to provide osteopathic continuing medical education for physicians. The AOA Bureau of OMED, as a co-sponsor with Med Learning Group, designates this live program for a maximum of 1.5 AOA Category 2-A credits and will report CME and specialty credits commensurate with the extent of the physician’s participant in this live activity.

DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/ 

AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Med Learning Group prior to the live event at info@medlearninggroup.com

Feb
5
Tue
A 3D View: Improving Acute and Preventive Treatment of Migraine in the Primary Care Setting Using Novel Agents
Feb 5 2019 @ 12:00 am – Feb 4 2020 @ 12:00 am

A 3-D View: Improving Acute and Preventive Treatment of Migraine in the Primary Care Setting Using Novel Agents

View Activity

FACULTY

Anne H. Calhoun, MD, FAHS
Partner/Co-Founder, Carolina Headache Institute
Professor, Department of Anesthesiology
Professor, Department of Psychiatry
University of North Carolina
Chapel Hill, NC

Andrew Charles, MD
Professor of Neurology
Director, UCLA Goldberg Migraine Program
Meyer and Renee Luskin Chair in Migraine and Headache Studies
David Geffen School of Medicine at
University of California
Los Angeles, CA

PROGRAM OVERVIEW

This case-based enduring activity will cover the treatment and management of patients with migraines.

TARGET AUDIENCE

This educational activity is intended for primary care providers and doctors of osteopathy working with patients with migraine headaches.

LEARNING OBJECTIVES

On completing the program, attendees should be able to:

  • Review best practices for diagnosing migraine headaches including the process of differential diagnosis
  • Assess efficacy and safety profiles of investigational agents for the acute treatment of migraine, as well as calcitonin-gene related peptide (CGRP)-targeting agents for the prevention of episodic and chronic migraine
  • Describe burdens associated with migraine headaches and the use of patient reported outcomes for measuring the impact of new and established migraine therapies
  • Discuss strategies for managing migraine that include the integration of novel treatment options and the application of methods for overcoming patient- and physician-dependent barriers in clinical practice

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to
provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.5 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in treating and managing patients with
migraine. CNE Credits: 1.5 ANCC Contact Hours

CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

AOA Credit: The AOA Bureau of OMED is accredited by the American Osteopathic Association to provide osteopathic continuing medical education for physicians. The AOA Bureau of OMED, as a co- sponsor with Med Learning Group, designates this enduring program for a maximum of 1.5 AOA Category 2-A credits and will report CME and specialty credits commensurate with the extent of the physician’s participant in this enduring activity.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Anne Calhoun, MD, is a consultant for Amgen, Depomed, Lilly, and Teva and is on the speakers bureau for Amgen, Avanir, Depomed, Lilly, Merck, Pernix, and Teva. She previously conducted research for Allergan, Autonomic Technologies, ElectroCore, Scion Neurostim, and Avanir.

Andrew Charles, MD, is a consultant for Alder, Amgen, Biohaven, Eli Lilly, and eNeura. He has conducted research for Takeda Pharmaceuticals.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE CONTENT REVIEW
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to
products or devices they or their spouse/life partner have with commercial interests related to the
content of this CME/CNE activity:

Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group has nothing to disclose.
Ana Maria Albino, Program Manager of Med Learning Group has nothing to disclose.
Chris Drury, Scientific and Medical Services of Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, faculty may mention the use of medications for both FDA-approved and non- approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures.
2. Participate in the online activity.
3. Submit the evaluation form to Med Learning Group.

Participants will receive their certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at http://medlearninggroup.com/privacy‐policy/

RELEASE DATE: February 5, 2019

EXPIRATION DATE: February 5, 2020

View Activity

Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Feb
6
Wed
Summit Meeting – San Diego, CA @ THE WESTIN SAN DIEGO
Feb 6 @ 5:30 pm – 7:30 pm

A 3D View: Improving Acute Preventive Treatment of Migraine in Primary Care Setting Using Novel Agents

WEDNESDAY, FEBRUARY 6, 2019

5:30 PM – 6:00 PM Registration / Dinner
6:00 PM – 7:30 PM Meeting

VENUE

THE WESTIN SAN DIEGO
400 West Broadway
San Diego, CA 92101
MEETING ROOM: Emerald Ballroom

1.5 CME/CNE Credits: A 3D View!

  • 3D GLASSES PROVIDED TO ALL ATTENDEES

Features:

  • Interactive, case-based learning environment
  • Create your own Personalized Poster
  • iPads provided to enhance learning experience and enable real-time Q&A

REGISTRATION INFORMATION

To register for the live event meeting or simulcast, please visit www.MLG-Migraine.com or call 207-406-4248.

FACULTY

Anne H. Calhoun, MD, FAHS
Partner/Co-Founder, Carolina Headache Institute
Professor, Department of Anesthesiology
Professor, Department of Psychiatry
University of North Carolina
Chapel Hill, NC

Andrew Charles, MD
Professor of Neurology
Director, UCLA Goldberg Migraine Program
Meyer and Renee Luskin Chair in Migraine and Headache Studies
David Geffen School of Medicine at
University of California
Los Angeles, LA

AGENDA

I. Overview of headache disorders

  • The burden of migraine: epidemiology, disability and quality of life, economic burden
  • Migraine and other primary headaches: classification and diagnosis of primary headache disorders
  • Patient video showing the process of differential diagnosis – leading into treatment

II. The current challenges and needs in migraine management

  • Expanding role for primary care providers and doctors of osteopathy
  • Evidence-based approach to acute and preventive treatment of migraine
  • Abortive agents in development: lasmiditan, gepants, new delivery devices for existing agents
  • Migraine prevention: what are the current unmet needs?
  • Improving patient/physician and physician/physician communication

III. Targeting CGRP or its receptor: a new era in targeting migraine underlying pathology

  • Role of CGRP in the trigeminovascular system and in migraine
    • Mechanism of action of gepants and mAbs to CGRP or its receptor
  • Update of recently released data from clinical trials
  • Safety
  • Patient-reported outcomes
  • Interactive case studies, including refractory chronic migraine cases
  • Improving patient/physician and physician/physician communication

IV. Neuromodulation: a brief update

V. Conclusions and Q&A

EDUCATIONAL OBJECTIVES

  • Review best practices for diagnosing migraine headaches including the process of differential diagnosis
  • Assess efficacy and safety profiles of investigational agents for the acute treatment of migraine, as well as calcitonin-gene related peptide (CGRP)-targeting agents for the prevention of episodic and chronic migraine
  • Describe burdens associated with migraine headaches and the use of patient-reported outcomes for measuring the impact of new and established migraine therapies
  • Discuss strategies for managing migraine that include the integration of novel treatment options and the application of methods for overcoming patient- and physician-dependent barriers in clinical practice

TARGET AUDIENCE
This activity is intended for primary care providers and doctors of osteopathy working with patients with migraine headaches.

ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.5 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in treating and managing patients with migraine. CNE Credits: 1.5 ANCC Contact Hours

CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

ABIM Maintenance of Certification:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 AOA Credit:
The AOA Bureau of OMED is accredited by the American Osteopathic Association to provide osteopathic continuing medical education for physicians. The AOA Bureau of OMED, as a co-sponsor with Med Learning Group, designates this live program for a maximum of 1.5 AOA Category 2-A credits and will report CME and specialty credits commensurate with the extent of the physician’s participant in this live activity.

DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Med Learning Group prior to the live event at info@medlearninggroup.com

Jul
2
Thu
Diagnosing and Managing Primary Headache Disorders in the Primary Care Setting: Challenges and Opportunities
Jul 2 2020 @ 3:10 am – Jul 2 2021 @ 4:10 am

Diagnosing and Managing Primary Headache Disorders in the Primary Care Setting: Challenges and Opportunities

View Activity

FACULTY

Dawn Buse, PhD
Clinical Professor, Department of Neurology
Albert Einstein College of Medicine of Yeshiva University
Assistant Professor, Clinical Health Psychology Doctoral Program
Ferkauf Graduate School of Psychology of Yeshiva University
Board Member at Large, American Headache Society

Andrew Charles, MD
Professor of Neurology
Director, UCLA Goldberg Migraine Program
Meyer and Renee Luskin Chair in Migraine and Headache Studies
David Geffen School of Medicine at
University of California
Los Angeles, CA
President-Elect, American Headache Society

PROGRAM OVERVIEW

This case-based enduring activity will cover the treatment and management of patients with headache disorders, including migraine and cluster headache.

TARGET AUDIENCE

This activity is intended for primary care providers, including family practice physicians, physician assistants, and nurse practitioners who are involved in the care of patients with headache disorders, including migraine and cluster headache.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Implement best practices for the timely and accurate diagnosis of primary headache disorders in primary care settings and for referral to specialists when necessary
  • Identify the mechanisms of action and clinical profiles of new and emerging therapeutic options for the acute and preventative treatment of patients with primary headache disorders
  • Design individualized evidence-based treatment plans for patients with primary headache disorders, with focus on cluster headache, in the primary care setting
  • Utilize patient-specific factors to select therapies for patients with primary headache disorders, including quality-of-life assessment and goal setting
  • Implement strategies to effectively communicate with patients and educate them in order to establish treatment plans and encourage adherence

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this web-based activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the long-term treatment and management of patients with headache disorders, including migraine and cluster headache. CNE Credit: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

AMERICAN ASSOCIATION OF FAMILY PHYSICIANS

This activity, Diagnosing and Managing Primary Headache Disorders in the Primary Care Setting: Challenges and Opportunities from 06/29/2020–10/31/2020, has been reviewed and is acceptable for up to 1.00 elective credit by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN ASSOCIATION OF PHYSICIAN ASSISTANTS

This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid from 6/29/2020 to 10/31/2021. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-200671

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

FACULTY
Dawn Buse, PhD has received consulting fees from Amgen, Allergan, Biohaven, Dr. Reddy’s, Lilly, and Teva and research grant support from Amgen, Allergan, Dr. Reddy’s, and Lilly.

Andrew Charles, MD receives consulting fees from Alder, Amgen, Biohaven, Eli Lilly, and eNeura. He has conducted research for Takeda Pharmaceuticals.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Ashley Whitehurst, Program Manager of Med Learning Group, has nothing to disclose.
Chris Drury, Medical Director of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

RELEASE DATE: July 2, 2020

EXPIRATION DATE: July 2, 2021

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

View Activity

Oct
26
Mon
Diagnosing and Managing Primary Headache Disorders in the Primary Care Setting: Challenges and Opportunities
Oct 26 2020 @ 7:28 am – Oct 26 2021 @ 8:28 am

Diagnosing and Managing Primary Headache Disorders in the Primary Care Setting: Challenges and Opportunities

View Activity

FACULTY

Dawn Buse, PhD
Clinical Professor, Department of Neurology
Albert Einstein College of Medicine of Yeshiva University
Assistant Professor, Clinical Health Psychology Doctoral Program
Ferkauf Graduate School of Psychology of Yeshiva University
Board Member at Large, American Headache Society
Andrew Charles, MD
Professor of Neurology
Director, UCLA Goldberg Migraine Program
Meyer and Renee Luskin Chair in Migraine and Headache Studies
David Geffen School of Medicine at University of California
President-Elect, American Headache Society
Los Angeles, CA

PROGRAM OVERVIEW

This case-based enduring activity will cover the treatment and management of patients with headache disorders, including migraine and cluster headache.


TARGET AUDIENCE

This activity is intended for primary care providers, including family practice physicians, physician assistants, and nurse practitioners who are involved in the care of patients with headache disorders, including migraine and cluster headache.


LEARNING OBJECTIVES

  • Implement best practices for the timely and accurate diagnosis of primary headache disorders in primary care settings and for referral to specialists when necessary
  • Identify the mechanisms of action and clinical profiles of new and emerging therapeutic options for the acute and preventative treatment of patients with primary headache disorders
  • Design individualized evidence-based treatment plans for patients with primary headache disorders, with focus on cluster headache, in the primary care setting
  • Utilize patient-specific factors to select therapies for patients with primary headache disorders, including quality-of-life assessment and goal setting
  • Implement strategies to effectively communicate with patients and educate them in order to establish treatment plans and encourage adherence

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.


CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.5 AMA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.


NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the long-term treatment and management of patients with headache disorders, including migraine and cluster headache.
CNE Credits: 1.5 ANCC Contact Hours.


CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.5 contact hours of continuing nursing education of RNs and APNs.


DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.


DISCLOSURE OF CONFLICTS OF INTEREST

Dawn Buse, PhD has received consulting fees from
Amgen, Allergan, Biohaven, Dr. Reddy’s, Lilly, and Teva and research grant support from Amgen, Allergan,
Dr. Reddy’s, and Lilly.
CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.
Andrew Charles, MD receives consulting fees from Alder, Amgen,
Biohaven, Eli Lilly, and eNeura. He has conducted research for Takeda Pharmaceuticals.
CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Ashley Whitehurst, Program Manager of Med Learning Group, has nothing to disclose.
Chris Drury, Medical Director of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.


DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the enduring activity; and
  3. Complete pre-and-post surveys and evaluation.

Participants will receive their certificate as a downloadable file.


DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

RELEASE DATE: October 26, 2020

EXPIRATION DATE: October 26, 2021

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group at info@medlearninggroup.com

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Apr
7
Wed
Online Simulation Center: “Challenges in Diagnosing and Managing Migraine in the General Neurology and Primary Care Settings: Opportunities for Improved Patient Outcomes”
Apr 7 2021 @ 12:00 am – Apr 7 2022 @ 11:45 pm

Online Simulation Center: “Challenges in Diagnosing and Managing Migraine in the General Neurology and Primary Care Settings: Opportunities for Improved Patient Outcomes”

VIEW ACTIVITY

FACULTY

Dawn Buse, PhD
Clinical Professor, Department of Neurology
Albert Einstein College of Medicine
Assistant Professor, Clinical Health Psychology Doctoral Program
Ferkauf Graduate School of Psychology of Yeshiva University
Board Member at Large, American Headache Society
San Diego, CA
Uwe Reuter, MD, PhD, MBA
Professor of Neurology
Charité Universitätsmedizin Berlin
Center for Neurology, Neurosurgery, and Psychiatry
Berlin, Germany

PROGRAM OVERVIEW

This online, case-based, practice-focused activity will cover diagnosis and management strategies for headache disorders, including migraine.

TARGET AUDIENCE

This activity is intended for general neurologists and primary care providers involved in the care of patients with headache disorders, including migraine.

LEARNING OBJECTIVES

On completing the program, attendees should be able to:

  • Provide early and accurate diagnoses of headache disorders using current diagnostic criteria, best practices for differential diagnosis, and diagnostic assessment tools
  • Reduce the delay in referrals to neurologists for those patients failing to respond to standard of care therapies in the primary care setting
  • Identify patients who would benefit from acute, preventative, or both therapeutic options, and choose therapies using current evidence-based guideline recommendations
  • Apply new clinical trial data on novel agents with distinct mechanisms of action and efficacy/safety profiles for the acute and preventative treatment of migraine
  • Assess quality of life and migraine burden of individual patients to inform treatment paths that seek to improve their symptoms and achieve pain freedom

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/Conference Complete Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission of Accreditation.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with migraine.
CNE Credits: 1.0 ANCC Contact Hour(s).

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dawn Buse, PhD has received consulting fees from Amgen, Allergan, Biohaven, Lilly, and Teva and has received research grant support from Amgen, Allergan, the National Headache Foundation, and the US FDA.

Uwe Reuter, MD, PhD, MBA has received consulting fees from AbbVie, Allergan Eli Lilly, Novartis, Lundbeck and Teva. He serves on the Speaker Bureau for AbbVie, Allergan, Eli Lilly, Novartis, Medscape and Teva. He received non-CME/CE from Novartis. He is an Associate Editor of the Journal of Headache and Pain and Frontiers in Neurology.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Felecia Beachum, Program Manager for Med Learning Group, has nothing to disclose.
Marcello Morgan, MD, MPH, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CNE credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the online activity.
  3. Complete posttest and evaluation form online.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

RELEASE DATE: April 7, 2021

EXPIRATION DATE: April 7, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

VIEW ACTIVITY